Chemotherapy in small cell lung cancer: a consensus report

[1]  Mark R. Green.  Phase III chemotherapy trials in small cell lung cancer , 1989 .

[2]  T. Splinter.  Chemotherapy of small-cell lung cancer: duration of treatment , 1989 .

[3]  M. Cullen.  The design of phase II trials , 1989 .

[4]  David H. Johnson.  New drugs in the management of small cell lung cancer , 1989 .

[5]  D G Lowe,et al.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Begg,et al.  A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Hainsworth,et al.  Chronic daily administration of oral etoposide--a phase I trial. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Mastrangelo,et al.  The pathophysiology and staging of cutaneous malignant melanoma. , 1989, Seminars in oncology.

[9]  J. Machiels,et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Holle,et al.  Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Cullen,et al.  Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease. , 1987, Cancer treatment reports.

[12]  M. Slevin,et al.  Phase II trial of mitoxantrone as first-line chemotherapy for extensive small cell lung cancer. , 1987, Cancer treatment reports.

[13]  D. Osoba,et al.  Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. , 1987, Annals of internal medicine.

[14]  D. Osoba,et al.  Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Giaccone,et al.  4'-Deoxydoxorubicin, an inactive drug in small cell lung cancer. , 1987, European journal of cancer & clinical oncology.

[16]  J. Sculier,et al.  Intensive chemotherapy in small cell lung cancer. , 1986, European journal of cancer & clinical oncology.

[17]  H. Hansen,et al.  Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Hansen,et al.  Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. , 1983, Cancer treatment reports.